Bayer Takes Over Saridon Trademark Lawsuit From Roche
This article was originally published in PharmAsia News
China's Supreme Court recently accepted Southwest Pharmaceutical's appeal to have a retrial of its trademark violation case, the firm's final chance to keep its Saridon (sanlietong) trademark after two failed attempts. The lawsuit between Southwest Pharmaceutical and Roche has dragged for more than a decade; now a new player joins in the fray. Roche has transferred Saridon's production and trademark to Bayer, thus passing the hot potato to the new owner. Bayer declines to comment on the lawsuit retrial, but points out that Saridon plays an important role in its developing China's generic drug market. Analysts believe that the corporation will not sit idly by and do nothing about the Sanlietong issue. (Click here for more - Chinese Language)
You may also be interested in...
New report shows average out-of-pocket cost per prescription of $10.67 in 2019 was unchanged from 2018. But while the number of dispensed drugs barely increased, sales jumped more than 5%.
The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.